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Abstract: Cannabis legalization is currently a topic of significant
interest within the American healthcare system. Existing research
has demonstrated the effects of medical cannabis in alleviating
manifestations of several common health conditions which affect
many Americans, including cancer and chronic pain. Additionally,
research has demonstrated that medical cannabis programs have
positive implications for the objectives of government health
initiatives such as the Institute for Healthcare Improvement (IHI)
Triple Aim. Economic benefits from cannabis taxation have also
been documented in states with active medical cannabis programs.
While federal restrictions inhibit extensive cannabis research,
the legalization of medical cannabis has significant implications
for the American healthcare system in terms of cost, access, and
quality. This paper is a review of current literature and research
regarding medical cannabis legalization in the United States.
Keywords: healthcare, cannabis, medical cannabis, United States

The issue of legalizing cannabis for medical use has become one of
the top-discussed health topics in recent years. With 27 states and the District
of Columbia participating in active medical cannabis programs, much of the
movement’s effort is now focused on developing arguments to persuade
the remaining states to implement similar legislation. The legalization
of cannabis for both medical and recreational purposes has benefits and
drawbacks, but this paper will focus on support for medicinal legalization.
History and Current Status of Legalization
The use of cannabis, or marijuana, for medicinal purposes dates
back to the 15th century, when the first written mention of the drug was
found in an ancient Chinese medical book, the Rh-Ya (Historical Timeline,
2017). In the United States, marijuana was a common prescription for a
variety of health conditions until 1937, when the Marihuana Tax Act of
1937 effectively criminalized and prohibited the drug (Historical Timeline,
2017). Since then, numerous advocacy groups, politicians, and social
movements have attempted to expand the legalization of marijuana for both
recreational and medicinal purposes. The general strategy is to use medical
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legalization as a stepping stone to full legalization, and rightfully so. Recent
research has shown marijuana to be effective in managing manifestations
of numerous health conditions that are among the most prevalent in
America, including cancer, HIV/AIDS, chronic pain, and glaucoma
(Bradford & Bradford, 2016), and with less harmful effects than some
commonly-prescribed pharmaceuticals. As it currently stands, national and
state legislature are significantly divided on the topic of medical cannabis
legalization. At the national level, possession of marijuana for any purpose
is still illegal, meaning that patients in possession of the drug in medicallylegal states could still potentially incur criminal charges on the federal level
(Johannigman & Eschiti, 2013). This discrepancy stems in part from the
federal classification of marijuana as a Schedule I drug, which the Controlled
Substances Act of 1970 defines as having “no currently acceptable medical
use in treatment in the United States, a high potential for abuse, and a lack
of accepted safety for use under medical supervision (Bradford & Bradford,
2016).” This classification places cannabis in the same category of opiates
such as heroin and morphine (Controlled Substances Act) and significantly
inhibits the cultivation and acquisition of cannabis for prescriptive use and
for further research on its effects in treating various health conditions. From
what little cannabis research has been done, considerable implications have
been found for two health issues currently at the forefront of the American
healthcare field: cancer and opioid overdose.
Relevance to National and Community Health
Cancer. According to the Center for Disease Control, cancer is the
second leading cause of death in the United States, claiming nearly 600,000
lives in 2015. In the state of Kentucky alone, there were over 10,000 deaths
from cancer in 2015, making it the state’s leading cause of death (“Cancer
Rates by U.S. State,” 2016). In states with operational medical cannabis
programs, cancer is a qualifying condition for prescription, and use of the
drug as it has proven effective in managing side effects of chemotherapy
such as nausea, loss of appetite, and pain (Johannigman and Eschiti,
2013). Additionally, a 2014 study by Scott, Dalgleish, and Liu found that
tetrahydrocannabinol (THC), the major active component of cannabis,
reduced the size of certain cancer cells and inhibited the process of cell
proliferation by interfering with cell communication mechanisms (Scott et
al., 2014). While the results of this particular study only discovered these
properties in glioma cells, the data “add further support to the concept
that cannabinoids both alone and in combination with each other, possess
anticancer properties” (Scott et al., 2014).
Opioid overdose. The second prominent national and community
health issue pertaining to medical cannabis legalization is opioid overdose.
While illegal opioids such as heroin were responsible for nearly 13,000
deaths in the United States in 2015, over 15,000 of the nation’s opioid-related
deaths in the same year were caused by prescription opioids alone (National
https://encompass.eku.edu/kjus/vol2/iss1/2
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Center for Health Statistics, 2017). These prescription opioids include
methadone, oxycodone, and hydrocodone, and are usually prescribed to
patients with chronic pain, a common health condition in the United States.
According to an investigation by Bachhuber et al. (2014), chronic pain is
also the primary indication for medical cannabis prescription in states with
active laws. Subsequent research found that in states with medical cannabis
laws, the mean annual rate of opioid overdose was 24.8% lower than in
states without medical cannabis laws. From these results, it is predicted that
“patients with chronic [noncancer] pain who would have otherwise initiated
opioid analgesics may choose medical cannabis instead” (Bachhuber et al.,
2014), and therefore contribute to lower rates of prescription opioid overdose
and death. If substantiated by further research, these findings could prove
to be significant for Kentucky in particular; according to the Overdose
Fatality Report released by the Kentucky Office of Drug Policy, over 1,000
Kentuckians die from drug overdose per year (Tilley & Ingram, 2015).
Among the most commonly detected drugs in these cases were morphine
(45%), fentanyl (34%), oxycodone (23%), and hydrocodone (21%), all of
which are commonly prescribed analgesic opioids (Tilley & Ingram, 2015).
While the research on these health issues has strong implications, it lacks
volume; current federal legislation regarding medical marijuana inhibits its
accessibility for clinical and scientific research. The legalization of medical
marijuana on a federal level would eliminate these barriers and allow for
more thorough and interdisciplinary research on the effects of cannabis on
cancer, opioid overdose, and an array of other health conditions, making
this an important healthcare issue on both national and community levels
in the United States. In addition, the legalization of medical cannabis could
have significant impacts on central concepts of the U.S. healthcare delivery
framework as well.
Impact on Healthcare Delivery and Impacted Populations
The three cornerstones of the healthcare delivery system are cost,
access, and quality (Shi & Singh, 2015).
Cost. In the realm of healthcare, cost carries a different meaning
based on the perspective from which it is viewed; consumers and providers
place cost into a “price” context, while government defines it as “national
expenditures.” While research on the “price” of medical cannabis is limited
due to lack of cannabis accessibility, some research has been done on the
impact of medical cannabis on national healthcare expenditures. In a 2016
study, Bradford & Bradford performed an analysis of Medicare Part D
spending data for prescription drugs from 2010 to 2013. The researchers
limited the analysis to drugs prescribed for conditions for which medical
marijuana is considered an alternative method of treatment: anxiety,
depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders,
and spasticity. The study’s results indicated that in states with active
medical marijuana policies, all of the conditions except glaucoma had fewer
Published by Encompass, 2018
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drug prescriptions written than in states without legal medical marijuana.
This translated to a Medicare Part D and enrollee spending reduction of
$165.2 million in 2013 when totaled across the 17 states and the District
of Columbia, all of which had legal medical marijuana laws at that time
(Bradford & Bradford, 2016). If all states had had active medical marijuana
laws in 2013, the study projected that Medicare Part D expenditures would
have been reduced by $468.1 million (Bradford & Bradford, 2016).
Access. The cornerstone of access refers to “the ability of a person to
obtain health care services when needed” (Shi and Singh, 2015). Access is
considered “one of the key determinants of health” (Shi and Singh, 2015), and
is a valuable assessment tool in evaluating the effectiveness of a healthcare
delivery system. In the case of medical cannabis, access is fragmented and
inconsistent due to varying state policies and federal restrictions. Medical
marijuana patients, as well as healthcare practitioners, who live in legalized
states are still subject to criminal possession charges, and face difficulty
accessing the drug in other states due to varying requirements and approved
indications. As summarized by J. Michael Bostwick, MD. (2012),
Without a federal umbrella, regulations lack any state-to-state
uniformity about what constitutes acceptable indications, appropriate
prescriber-patient relationships, or legitimate means of acquiring botanical
cannabis…physicians who prescribe medical marijuana are susceptible to
prosecution under the same statutes as drug dealers.
Legalizing medical cannabis on a national level would provide
consistent regulations across all states, thereby increasing access to medical
cannabis for all patient populations with approved indications.
Quality. The third cornerstone, quality, is defined as “the degree to
which health services for individuals and populations increase the likelihood
of desired health outcomes and are consistent with current professional
knowledge” (Shi and Singh, 2015). Despite the emerging research
evidencing positive health effects of medical cannabis, many medical and
legislative professionals remain staunchly opposed. Much of this hesitation
comes from assumption that medical cannabis must be smoked in order to
be effective and the negative implications that may have one one’s health; in
the words of Johannigman and Eschiti, “Smoking of any substance has been
linked to lung cancer, which carries the highest mortality rate of any cancer
type in the United States” (2013). While marijuana smoke inhalation is the
most common method of usage and the quickest way to experience its effects
(“How Marijuana is Consumed”, 2016), the lung and throat irritation and
damage caused can make certain health conditions worse. Oral consumption
of marijuana, or “edibles”, is often preferred by medicinal patients; chronic
pain patients in particular have reported that the effects of orally ingested
marijuana last longer, reducing the number of doses required to achieve pain
relief (“How Marijuana is Consumed”, 2016). For more superficial health
conditions such as muscle pain, stiffness, swelling, and neuralgia, topical
cannabis products can be applied in the form of cream, lotion, or salve. The
cannabinoids in the topical product interact with CB1 and CB2 receptors
https://encompass.eku.edu/kjus/vol2/iss1/2
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in the skin, providing pain relief and anti-inflammatory effects without
the psychoactive effects associated with inhaled and ingested cannabis
(“Cannabis 101”, 2016). Topical administration of cannabis is often popular
with older adult populations due to its effective management of localized
pain and lack of psychoactive effects (“Cannabis 101”, 2016). Overall,
the various forms of marijuana ingestion allow for healthier alternatives
to chemical medication, and the positive effects of the drug that have been
revealed through research could improve the quality of life for countless
Americans and Kentuckians alike.
Current federal restrictions limit opportunities for medical marijuana
prescription and clinical research. However, legalization of medical cannabis
would provide regulations for the cultivation and production of cannabis
and cannabis byproducts, which would provide populations such as chronic
pain patients, cancer patients, and older adults with the safest and highest
quality form of medical cannabis for their specific health conditions and
needs. Therefore, legalization of medical cannabis has significant positive
implications for the facets of cost, access, and quality within the American
healthcare delivery system.
Applications
As previously addressed, research suggests that the healthcare
delivery cornerstones of cost, access, and quality could face significant
alterations with the legalization of medical cannabis. In a similar vein,
medical cannabis legalization has positive potential implications for each
objective within the Institute for Health Improvement (IHI) Triple Aim. The
objectives of the IHI Triple Aim are experience of care, population health
and per capita cost (“The IHI Triple Aim”, 2016).
Experience of care. In a study by Reiman (2008), patient care
experience ratings from 130 adult medical cannabis patients were collected
via questionnaire and analyzed. The results of the study yielded an 80% or
higher satisfaction rating in three of the four satisfaction dimensions, which
included General, Interpersonal, Access, and Privacy satisfaction (Reiman,
2008, p.35). These results indicate that the interdisciplinary services of
medical cannabis programs improve patient healthcare experience; as stated
by Reimer (p. 40), “the social support offered to medical cannabis patients
provides an escape and a way to cope.”
Population health. As referenced in the Relevance to National
and Community Health section, medical cannabis has been shown to be
effective in managing two of the most prominent health concerns in the
United States: cancer and opioid addiction. In addition, research by Reimer
(2008) suggests that medical cannabis programs improve population
health by implementing a more holistic approach to patient care. Reimer
acknowledges the positive effects of social support and teaching of healthy
coping mechanisms on patient satisfaction, stating that “primary physical
and mental health services might have a better chance of achieving their
intended effect if clients are receiving additional social support and coping
Published by Encompass, 2018
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services” (p. 40).
Per capita cost. While current national policies restrict the scope
of research on medical cannabis and per capita cost in the United States,
economic benefits have been observed in states with active medical cannabis
programs. In particular, research has highlighted benefits in the arenas of
Medicare Part D spending and taxation profits. A study by Bradford &
Bradford (2013) attributes the reduction in Medicare Part D spending to
fewer pharmaceutical prescriptions in states with active medical cannabis
programs. Significant taxation revenue has also been noted in these states.
A review of 2016 Tax Foundation Reports showed that Colorado, a state
with one of the most established medical cannabis programs, collected
approximately $140 million in marijuana taxes in 2016 (Ekins & Henchman,
2016).
Application to Occupational Science
Through the lens of occupational science, the legalization of medical
cannabis would also fulfill the ideal of occupational justice. Nilsson and
Townsend (2010) define occupational justice as “a justice that recognizes
occupational rights to inclusive participation in everyday occupations for
all persons in society, regardless of age, ability, gender, social class, or other
differences.” Occupational injustice, or situations in which occupational
justice is absent, takes several different forms; occupational deprivation is
a form of occupational injustice which connects to the legal ramifications
surrounding medical cannabis. According to Whiteford (2003), occupational
deprivation is “a state of prolonged preclusion from engagement in
occupations of necessity and/or meaning due to factors that stand outside
the control of the individual.” In the case of medical cannabis patients, the
inconsistencies and legal restrictions of the medical cannabis industry pose
potential difficulties in terms of acquiring the needed dosages, accessing
proper cannabis products such as edible forms and topical substances, and
legal protection in states where medical cannabis is not yet legal. As such,
there could be situations in which chronic pain patients, cancer patients, or
patients with a number of other health conditions cannot gain access to their
source of symptom management. This could result in acute manifestations
of symptoms such as pain, nausea, vomiting, and loss of appetite, making
it difficult if not impossible for these patients to participate in activities of
daily living, leisure activities, and social participation.
Application to Healthcare Practitioner Role
As healthcare practitioners, a significant part of those roles is to
advocate for clients and their rights and needs. Investigating topics such
as the legalization of medical cannabis and its implications for healthcare
delivery in America is an important educational opportunity as it is a
current and highly controversial issue that is becoming a prevalent topic of
https://encompass.eku.edu/kjus/vol2/iss1/2
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discussion in political, academic, and medical arenas.
Relevance
Relevance to Current Policies
In the political, academic, and medical realms, policies are
constantly changing and modifying to include new regulations, restrictions,
and penalties. Additionally, public health and safety policies are constantly
adapting to accommodate medical cannabis as new states begin to consider
its legalization. As the first state in the nation to have legalized both
medical and recreational cannabis (Ghosh et al., 2016), the public health
framework of Colorado has been studied and serves as a valuable reference
for states desiring to implement similar policies. To improve consistency
and effectiveness of its policies, Colorado has adopted a multidisciplinary
approach to working on cannabis-related issues; experts from a variety
of public agencies such as human services, public safety, education, and
health care work together to establish regulations for cannabis production
and distribution that both “respect the intention of the voters while striving
to mitigate negative outcomes (Ghosh et al., 2016).” One of the key
components and core values of Colorado’s policy development is education
(Ghosh et al., 2016), to which end they implemented the “Good to Know
Colorado” campaign. The campaign’s purpose is to provide educational
messages and materials to the residents of Colorado regarding safe, legal,
and responsible marijuana use; this includes information about secondhand
smoke reduction, combining marijuana with other substances, and the
dangers of using marijuana while underage (Ghosh et al., 2016). The
“Good to Know Colorado” campaign is reminiscent of other public policy
education efforts nationwide, and is an invaluable component of the public
health framework. The Colorado policymakers report that one of the most
significant challenges to their work has been discord between local, state,
and federal laws regarding cannabis. A reference to limited potential for
research is made in their report; “Research to assess both the beneficial
and the adverse health effects of marijuana’s Schedule I drug designation
applied by the U.S Drug Enforcement Agency (Ghosh et al., 2016).”
Implications for Healthcare Delivery
The legalization of medical marijuana would carry many positive
implications for the healthcare delivery system. With legalization on a
national level, federal regulations could be implemented to streamline the
medical cannabis industry, product cultivation, and product distribution,
ultimately making the drug more accessible to a larger patient population.
Further research on cannabis’s effects on health conditions such as cancer
and chronic pain could substantiate current research findings, and increased
prescription of medical cannabis could reduce Medicare Part D spending and
Published by Encompass, 2018
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private insurance costs in the pharmaceutical realm. Overall, the utilization
of medical marijuana as an intervention for pain and symptom management
demonstrates significant implications for improved patient quality of life as
evidenced by current research.
Consequences for Healthcare Delivery
In addition to the consequences of reducing healthcare costs,
increasing accessibility, and increasing overall patient quality of life, the
legalization of medical cannabis is a potential source of significant revenue
at both state and federal levels. According to a 2016 Tax Foundation report,
states with full legalization of marijuana have seen revenue collections
that far exceeded their initial projections; Colorado, anticipating an annual
collection of $70 million in marijuana tax, was on track to collect over $140
million by the end of 2016 (Ekins & Henchman, 2016). The report predicts
that if all states legalized cannabis, there would be a collective revenue of
$5 billion to $18 billion per year (Ekins & Henchman, 2016). On a federal
level, the report proposes that an excise tax on marijuana similar to that on
cigarettes would yield $500 million in revenue, while a 10% sales tax on
cannabis products is projected to raise $5.3 billion (Ekins & Henchman,
2016).
Conclusion
Current research supports the idea that nationwide legalization
of medical cannabis would offer improvements to the three healthcare
cornerstones of cost, access, and quality. In short, medical cannabis
legalization would lower healthcare expenditures on pharmaceuticals,
increase accessibility of the drug to include a larger patient population, and
improve overall patient quality of life by offering cannabis in various forms
for use. The public health policy frameworks of legalized states such as
Colorado can be taken into consideration when developing federal and state
policies and regulations. Medical cannabis legalization has implications to
increase tax revenue on individual state and federal levels, and government
regulations would work to streamline the cultivation, production, and
distribution of cannabis and its byproducts. With full legalization, jobs
would be created within the industry in the form of farming, production,
and dispensary positions. Client and caregiver education, much like the
“Good to Know Colorado” campaign, are crucial in order to promote safe,
legal, and responsible cannabis use. While the issue of medical marijuana
legalization is controversial, the research presented within this document
strongly suggests that further investigation is warranted and has significant
implications for improvements within the healthcare delivery system.
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